Federal University of Sao Paulo
São Paulo, 04039030, Brazil
NCT Number: NCT01014793
In acromegaly, nearly 40% of patients fail to control GH/IGF-I levels with somatostatin analogues (SA). Dopaminergic agonists (DA) are even less effective, but combination therapy with SA and DA normalizes IGF-I levels in 33-56% of patients in short-term studies. This study was designed to evaluate short and long term efficacy of cabergoline in controlling IGF-I levels in acromegalic patients receiving octreotide.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Observational
São Paulo, 04039030, Brazil
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal
Other names: cabergoline-Dostinex
Time frame: six months
Time frame: six months
Looking for future studies?
Notify MeFederal University of São Paulo
Other
Short and Long Term Efficacy of Combined Treatment in Controlling IGI-I Levels in Acromegaly
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07663318
Acromegaly, Bone Diseases
Zibo, Shandong, China
View Trial DetailsNCT07814651
Acromegaly, Bone Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT04076462
Acromegaly, Bone Diseases
Los Angeles, California, United States
View Trial DetailsNCT05131100
Acromegaly, Bone Diseases
Seoul, South Korea
View Trial Details